0001179110-21-000538.txt : 20210112 0001179110-21-000538.hdr.sgml : 20210112 20210112161550 ACCESSION NUMBER: 0001179110-21-000538 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210108 FILED AS OF DATE: 20210112 DATE AS OF CHANGE: 20210112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hill Emily Luisa CENTRAL INDEX KEY: 0001778279 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 21523660 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 edgar.xml FORM 4 - X0306 4 2021-01-08 0 0001070081 PTC THERAPEUTICS, INC. PTCT 0001778279 Hill Emily Luisa C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 0 1 0 0 Chief Financial Officer Common Stock 2021-01-08 4 M 0 2430 30.86 A 26552 D Common Stock 2021-01-08 4 S 0 2430 69.75 D 24122 D Common Stock 2021-01-08 4 M 0 3825 11.23 A 27947 D Common Stock 2021-01-08 4 S 0 3825 69.75 D 24122 D Common Stock 2021-01-08 4 M 0 10500 18.01 A 34622 D Common Stock 2021-01-08 4 S 0 10500 69.75 D 24122 D Common Stock 2021-01-08 4 M 0 9278 33.02 A 33400 D Common Stock 2021-01-08 4 S 0 9278 69.75 D 24122 D Stock Option (Right To Buy) 30.86 2021-01-08 4 M 0 2430 30.86 D 2026-01-03 Common Stock 2430.0 0 D Stock Option (Right To Buy) 11.23 2021-01-08 4 M 0 3825 11.23 D 2027-01-02 Common Stock 3825.0 0 D Stock Option (Right To Buy) 18.01 2021-01-08 4 M 0 10500 18.01 D 2028-01-03 Common Stock 10500 3500 D Stock Option (Right To Buy) 33.02 2021-01-08 4 M 0 9278 33.02 D 2029-01-21 Common Stock 9278 11932 D Stock Option (Right To Buy) 43.69 2024-09-24 Common Stock 7000.0 7000 D Stock Option (Right To Buy) 51.0 2025-01-02 Common Stock 1620.0 1620 D Stock Option (Right To Buy) 40.1 2029-05-30 Common Stock 50000.0 50000 D Stock Option (Right to Buy) 51.16 2030-01-28 Common Stock 64250 64250 D Stock Option (Right to Buy) 66.49 2031-01-05 Common Stock 63000 63000 D The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. Currently exercisable. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. This option was granted on May 31, 2019 and vests over four years, with 25% of the shares underlying the option vesting on May 31, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning August 31, 2020. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022. /s/ Avraham S. Adler, attorney-in-fact 2021-01-12